GALAPAGOS. PIONEERING FOR PATIENTS. WE DISCOVER. WE DARE. WE CARE.
LIVE

Serial Number

79300854

Owner

Galapagos N.V.

Attorney

Alexandra MacKay

Filing Date

Sep 22, 2020

Add to watchlist:

No watchlists yet
View on USPTO

GALAPAGOS. PIONEERING FOR PATIENTS. WE DISCOVER. WE DARE. WE CARE. Trademark

Serial Number: 79300854 • Registration: 6674439

GALAPAGOS. PIONEERING FOR PATIENTS. WE DISCOVER. WE DARE. WE CARE. is a trademark filed by Galapagos N.V. on September 22, 2020. The trademark is classified under Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Galapagos N.V. (6 trademarks)

Generaal de Wittelaan L11 A3
Mechelen BE-2800 , BE

Entity Type: 03

Trademark Details

Filing Date

September 22, 2020

Registration Date

March 22, 2022

Published for Opposition

January 4, 2022

Goods & Services

Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith

Medical services; medical and pharmaceutical advisory and consultancy services; gene bank services

Medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields; development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 11, 2022 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Aug 12, 2022 XXSS
GENERIC MADRID TRANSACTION CREATED
Aug 12, 2022 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 22, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 22, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 4, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jan 4, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Jan 1, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 15, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 15, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 15, 2021 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 1, 2021 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 30, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 28, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 28, 2021 CRFA
ASSIGNED TO LIE
Oct 28, 2021 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 23, 2021 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 1, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 1, 2021 GNSL
SUSPENSION LETTER WRITTEN
Oct 1, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 31, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 30, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 30, 2021 TROA
REFUSAL PROCESSED BY IB
Mar 22, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 2, 2021 RFCS
REFUSAL PROCESSED BY MPU
Mar 2, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Feb 23, 2021 RFCR
NON-FINAL ACTION WRITTEN
Feb 22, 2021 CNRT
ASSIGNED TO EXAMINER
Feb 9, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 16, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 12, 2021 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 24, 2020 REPR